×
Well done. You've clicked the tower. This would actually achieve something if you had logged in first. Use the key for that. The name takes you home. This is where all the applicables sit. And you can't apply any changes to my site unless you are logged in.

Our policy is best summarized as "we don't care about _you_, we care about _them_", no emails, so no forgetting your password. You have no rights. It's like you don't even exist. If you publish material, I reserve the right to remove it, or use it myself.

Don't impersonate. Don't name someone involuntarily. You can lose everything if you cross the line, and no, I won't cancel your automatic payments first, so you'll have to do it the hard way. See how serious this sounds? That's how serious you're meant to take these.

×
Register


Required. 150 characters or fewer. Letters, digits and @/./+/-/_ only.
  • Your password can’t be too similar to your other personal information.
  • Your password must contain at least 8 characters.
  • Your password can’t be a commonly used password.
  • Your password can’t be entirely numeric.

Enter the same password as before, for verification.
Login

Grow A Dic
Define A Word
Make Space
Set Task
Mark Post
Apply Votestyle
Create Votes
(From: saved spaces)
Exclude Votes
Apply Dic
Exclude Dic

Click here to flash read.

Comparing the survival times among two groups is a common problem in
time-to-event analysis, for example if one would like to understand whether one
medical treatment is superior to another. In the standard survival analysis
setting, there has been a lot of discussion on how to quantify such difference
and what can be an intuitive, easily interpretable, summary measure. In the
presence of subjects that are immune to the event of interest (`cured'), we
illustrate that it is not appropriate to just compare the overall survival
functions. Instead, it is more informative to compare the cure fractions and
the survival of the uncured sub-populations separately from each other. Our
research is mainly driven by the question: if the cure fraction is similar for
two available treatments, how else can we determine which is preferable? To
this end, we estimate the mean survival times in the uncured fractions of both
treatment groups ($MST_u$) and develop permutation tests for inference. In the
first out of two connected papers, we focus on nonparametric approaches. The
methods are illustrated with medical data of leukemia patients. In Part II we
adjust the mean survival time of the uncured for potential confounders, which
is crucial in observational settings. For each group, we employ the widely used
logistic-Cox mixture cure model and estimate the $MST_u$ conditionally on a
given covariate value. An asymptotic and a permutation-based approach have been
developed for making inference on the difference of conditional $MST_u$'s
between two groups. Contrarily to available results in the literature, in the
simulation study we do not observe a clear advantage of the permutation method
over the asymptotic one to justify its increased computational cost. The
methods are illustrated through a practical application to breast cancer data.

Click here to read this post out
ID: 251580; Unique Viewers: 0
Unique Voters: 0
Total Votes: 0
Votes:
Latest Change: July 8, 2023, 7:32 a.m. Changes:
Dictionaries:
Words:
Spaces:
Views: 34
CC:
No creative common's license
Comments: